Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
Pharma manufacturers must reconcile every batch against Schedule M (revised 2023) Good Manufacturing Practice batch-record requirements, finished-goods register, finished-goods packed register, dispatch register, distributor recall list, QR-code track-and-trace data for top 300 brands since 2023, CDSCO PvPI pharmacovigilance signals, batch recall recovery with bank receipt reversal, and Section 17(5)(h) ITC reversal on destroyed batches — all under phased Schedule M compliance running through December 2026.
Maintain a batch master keyed by manufacturing licence and Schedule M batch record; tie every batch through BOM consumption to API and excipient lots; reconcile finished-goods register against packed register against dispatch register at batch level; integrate QR-code data feed where applicable for top 300 brands; cross-reference CDSCO PvPI signals at batch level; on recall, reconcile dispatch quantity against return-received quantity per distributor and per batch; reverse Section 17(5)(h) ITC on destroyed batch inputs.
Pharma batch configuration with manufacturing licence master, Schedule M revised-2023 compliance phase tag per site, batch record register with API lot and excipient lot traceability, finished-goods packed register, dispatch register per distributor, QR-code feed integration for top 300 brands, CDSCO PvPI signal capture per batch, recall workflow with bank receipt reversal, Section 17(5)(h) ITC reversal builder.
A monthly batch close where every Schedule M batch record reconciles to BOM-to-API trail, finished-goods register ties to packed register and dispatch register, QR-code data confirms top 300 brand dispatch quantities to retail, CDSCO PvPI signals cross-reference correctly to manufacturing batches, recall recovery is tracked per distributor with bank receipt reversal, and Section 17(5)(h) ITC reversal flows through GSTR-3B for destroyed batches without double-counting against returns reconciliation.
A sterile injectable manufacturer in Visakhapatnam produces 60 batches per month across 8 SKUs — cardiovascular injectables (3 SKUs), oncology supportive care (2 SKUs), and anaesthesia adjuncts (3 SKUs) — supplying to government tenders, private hospitals and a small export book. The plant moved to the revised-2023 Schedule M framework on the early-phase compliance date and operates under a Pharmaceutical Quality System with electronic batch records. Two of the 8 SKUs are in the top-300 brand QR-code track-and-trace mandate. In a typical month the finance, quality and supply chain teams reconcile 60 batch records against finished-goods register, finished-goods packed register, dispatch register, distributor recall list (one active minor recall this month on a single SKU lot), CDSCO PvPI signal review at batch level, and the QR-code data feed for the two top-300 SKUs. The active recall — 320 units of one batch following a stability deviation observed at the in-house stability chamber — needs reconciliation against dispatch quantity to 24 hospitals, return quantity received, residual quantity in patient hands, credit notes issued, destruction certificate, bank receipt reversal of distributor payments, and Section 17(5)(h) ITC reversal on the destroyed batch inputs. Schedule M batch traceability reconciliation India is the operational backbone of pharma manufacturing in India — and the revised-2023 framework adds materially to the structured-data reconciliation surface.
Quick reference
| Item | Section / Rule | Detail |
|---|---|---|
| Schedule M (revised) | Drugs and Cosmetics Rules 1945 | Notified 2023; phased compliance through December 2026 |
| GMP scope | Schedule M Parts I-XII | Formulation, API, biological, blood products, sterile, non-sterile |
| Batch record requirements | Schedule M Part I and Annexures | Detailed batch manufacturing record and packaging record |
| QR-code track-and-trace mandate | Ministry of Chemicals notification | Top 300 brands by MAT; effective 1 August 2023 |
| Pharmacovigilance | CDSCO PvPI through IPC | Adverse drug reaction reporting at batch level |
| Recall framework | CDSCO recall guidelines | Class I (life-threatening), Class II, Class III |
| ITC reversal on destroyed batch | Section 17(5)(h), CGST Act | Blocks ITC on destroyed / written-off goods |
| GST law status | Unchanged by Income Tax Act 2025 | Section 17, Section 34 and Rule 53 continue as before |
What does Schedule M cover after the 2023 revision?
Schedule M of the Drugs and Cosmetics Rules 1945 prescribes Good Manufacturing Practice (GMP) requirements that every pharmaceutical formulation and API manufacturing plant in India must follow. The revised Schedule M was notified in 2023 with a phased compliance timeline running through December 2026 — larger plants moved first, MSME-classified plants given a longer runway.
The revision tightens several areas:
- Pharmaceutical Quality System (PQS) — mandates implementation of a structured PQS aligned with ICH Q10 principles
- Batch-record requirements — more detailed batch manufacturing record (BMR) and batch packaging record (BPR), with electronic records preferred
- Cross-contamination controls — strengthened requirements for dedicated facilities, change-over procedures, cleaning validation
- Sterile manufacturing — updated requirements for cleanroom classification, environmental monitoring, sterilisation validation
- Documentation — stronger expectations on data integrity, ALCOA principles (Attributable, Legible, Contemporaneous, Original, Accurate), audit trails
Reconciliation impact: every batch must now carry a more detailed audit trail from raw-material receipt through processing to dispatch, with electronic records preferred over paper-based logs. The Schedule M batch record becomes the source of truth that the finance reconciliation (BOM-to-finished-goods, finished-goods to dispatch) must align with.
The QR-code track-and-trace mandate for top 300 brands
Since 1 August 2023, the top 300 pharmaceutical brands in India (by Moving Annual Turnover, as notified by the Ministry of Chemicals and Fertilisers) are required to carry a QR code on the primary packaging that encodes traceability data. The QR code contains:
- Unique product identification code (UPIC)
- Manufacturer name and address
- Brand name and dosage form
- Batch number
- Manufacturing date and expiry date
- Manufacturing licence number
The QR code enables end-to-end traceability from manufacturer through stockist to retailer to patient. Scanning the code allows authentication of the pack and visibility of the dispatch trail.
For a manufacturer with two top-300 SKUs, reconciliation must hold the QR-code data captured at packaging line, the dispatch register at batch level, the distributor receipt confirmation, and (where the technology stack supports it) the secondary-sales pull-through visibility. Mismatches between the QR-code packed quantity and the dispatched quantity surface as a reconciliation exception that must be cleared before the batch is released.
CDSCO PvPI integration at batch level
The Pharmacovigilance Programme of India (PvPI), run by CDSCO through the Indian Pharmacopoeia Commission, captures adverse drug reaction (ADR) reports from healthcare providers, patients and manufacturers. Manufacturers operating under Schedule M are required to monitor ADRs at batch level — an ADR cluster linked to a specific batch can trigger a recall.
Reconciliation must hold the batch traceability such that an ADR signal at PvPI can be mapped back to:
- The manufacturing batch and BMR
- The BOM consumed (API lot, excipient lots, packaging components)
- The QC release records (assay, dissolution, content uniformity, sterility for injectables)
- The dispatch trail to distributors
- (Where QR-code track-and-trace applies) The further movement to retail
Failure to reconcile an ADR-flagged batch to its dispatch footprint delays recall execution and amplifies regulatory exposure. A typical monthly PvPI review at a 60-batch-per-month plant clears all signals — but when a signal does cluster, the speed of reconciliation determines the speed of recall.
What does a batch recall reconciliation involve?
A batch recall — voluntary by the manufacturer or directed by CDSCO — requires the manufacturer to recover every unit of the affected batch from the distribution chain. CDSCO guidelines classify recalls as:
- Class I — life-threatening situations
- Class II — temporary or reversible adverse health consequences possible
- Class III — unlikely to cause adverse health consequences
Reconciliation runs at the batch + distributor level:
- Original dispatch quantity to each stockist (from dispatch register)
- Returns received against the recall notice (per stockist)
- Residual quantity unaccounted-for (still in retail or patient hands)
- Credit notes issued for returned stock under Section 34 of the CGST Act (see pharma distributor return reconciliation for the credit-note mechanics)
- Destruction certificates for recovered stock
- Bank receipt reversal where the manufacturer refunds the distributor’s original payment
Where the QR-code track-and-trace data is available (top 300 brands), the recall recovery rate can be measured at retail or even patient level. Where it isn’t, recovery is measured at the distributor level only.
ITC reversal on destroyed batch under Section 17(5)(h)
When a batch is recalled and destroyed (rather than salvaged or reprocessed where regulatory permission allows), the ITC on the inputs that went into that batch must be reversed under Section 17(5)(h) of the CGST Act, which blocks ITC on goods destroyed.
The reversal flows:
- Identify the destroyed batch quantity (units × pack-equivalent)
- Trace through the BMR / BPR to the BOM consumption — API, excipients, primary and secondary packaging
- Calculate the original ITC on those inputs (input GST claimed when the inputs were purchased)
- Reverse the proportionate ITC in GSTR-3B for the period of destruction
- Maintain the destruction certificate, batch traceability and reversal entry in a reconciled file
The destruction certificate, the batch traceability under Schedule M and the GSTR-3B reversal entry must all reconcile to the same physical event. A destroyed batch without a clean reversal trail is an audit exposure on subsequent GST assessment. GST law on this point is unchanged by the Income Tax Act 2025 — Section 17(5)(h) continues to apply.
Worked example — sterile injectable manufacturer with 60 batches/month
A sterile injectable manufacturer in Visakhapatnam with 60 batches per month across 8 SKUs:
- Batches per month: 60; average batch size 12,000 units; total ~720,000 units packed
- Schedule M batch records: 60 BMRs and 60 BPRs reconciled monthly to finished-goods register
- QR-code track-and-trace SKUs: 2 of 8 (top 300 brands); 18,000 units per month packed under QR mandate; QR feed reconciled to dispatch register
- CDSCO PvPI signal review: zero active ADR signals in a typical month; reconciliation framework operational so that any future signal maps to BMR within hours
- Active recall: 320 units of one batch of cardiovascular injectable; dispatch was to 24 hospitals; 290 units recovered, 30 units unaccounted-for (consumed before recall); credit notes ₹4.8 lakh; destruction certificate issued; Section 17(5)(h) ITC reversal ~₹38,000 on traceable input GST
- Distributor / hospital service fees: ₹18 lakh monthly across 24 institutional accounts; Section 393(1)(a) code 1002 TDS at 2% (firms / hospitals) = ₹36,000 monthly challan
For the full code map see Section 393 TDS new Income Tax Act reconciliation and TDS payment codes 1001-1092 India.
How much is each batch-traceability exception costing your team?
Estimate the per-exception labour cost on batch-to-BOM-to-dispatch mismatches across your monthly Schedule M batch volume.
Open the three-way match exception cost calculator →For the authoritative current text of Schedule M (revised 2023), the GMP framework and the QR-code track-and-trace mandate, the Central Drugs Standard Control Organisation (CDSCO) portal is the source.
What automated reconciliation changes
Manual Schedule M batch traceability reconciliation across 60 batches per month — finished-goods register, packed register, dispatch register, QR-code feed, PvPI signal mapping, recall recovery, Section 17(5)(h) ITC reversal — is a multi-day month-end exercise even at a moderately-sized injectable plant. Purpose-built reconciliation software India treats the batch register, the BOM-to-finished-goods trail, the dispatch reconciliation, the QR-code feed integration, and the recall workflow as a structured variance stream and surfaces only the lines that fail to match. TransactIG carries 24+ industry presets, including a configuration that handles manufacturing licence master, Schedule M revised-2023 compliance phase tag, BMR / BPR linkage, QR-code data feed for top 300 brands, CDSCO PvPI signal capture, recall workflow with bank receipt reversal, and Section 17(5)(h) ITC reversal automation. Customer outcomes include match-rate improvement from 51% to 88%. Build is two-to-four weeks on AWS Mumbai (ISO 27001:2022). For the inbound three-way match rail see three-way matching software India.